Low risk (n = 818) | Intermediate risk (n = 1009) | p | ||
---|---|---|---|---|
Age(years) | 53.0 ± 8.5(27–79) | 53.2 ± 9.0(26–84) | 0.663a | |
Hypertension | yes | 175(21.4%) | 249(24.7%) | 0.106b |
no | 643(78.6%) | 760(75.3%) | ||
Diabetes | yes | 67(8.2%) | 82(8.1%) | 1.000b |
no | 751(91.8%) | 927(91.9%) | ||
Family history of malignant tumor | yes | 77(9.4%) | 73(7.2%) | 0.103b |
no | 741(90.6%) | 936(92.8%) | ||
Serum CA125 level | 18.08 ± 22.43 | 23.36 ± 32.67 | 0.023a | |
Histologic subtype | Endometrioid | 784(95.8%) | 971(96.2%) | 0.717b |
Areas of squamous differentiation | 34(4.2%) | 38(3.8%) | ||
Tumor grade | 1 | 757(92.5%) | 823(81.6%) | <0.001b |
2 | 61(7.5%) | 186(18.4%) | ||
Myometrial invasion | none | 339(41.4%) | 135(13.4%) | <0.001b |
Superficial (<50%) | 479(58.6%) | 874(86.6%) | ||
LVSI | yes | 18(2.2%) | 47(4.7%) | 0.005b |
no | 800(97.8%) | 962(95.3%) | ||
Lymphadenectomy | yes | 394(48.2%) | 624(61.8%) | <0.001b |
no | 424(51.8%) | 385(38.2%) |